Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

IPHA Relative to the S&P 500

IPHA Relative to the Sector

Seasonal Chart Analysis

Analysis of the Innate Pharma (NASD:IPHA) seasonal charts above shows that a Buy Date of December 17 and a Sell Date of March 10 has resulted in a geometric average return of 5.67% above the benchmark rate of the S&P 500 Total Return Index over the past 6 years. This seasonal timeframe has shown positive results compared to the benchmark in 5 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 6 years by an average of 36.91% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 6 years of data is available for shares of IPHA, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Herv Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fourni , and Fran ois Romagn on September 23, 1999 and is headquartered in Marseille, France.

To download IPHA seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: IPHA